Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) Stock Competitors & Peer Comparison
See MRVI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MRVI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRVI | $8.43 | -2.43% | 2.3B | -44.37 | -$0.19 | N/A |
| VRTX | $547.59 | -0.08% | 139B | 28.78 | $19.03 | N/A |
| REGN | $828.50 | -0.66% | 85.4B | 18.16 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,011.11 | -2.76% | 62.9B | 91.26 | $11.08 | N/A |
| MRNA | $138.89 | -4.30% | 55.1B | -17.04 | -$8.15 | N/A |
| RVMDW | $12.10 | +2.54% | 47.7B | -1.69 | -$7.21 | N/A |
| RVMD | $211.58 | +1.01% | 45B | -23.99 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $371.98 | -0.66% | 39.7B | 65.49 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
MRVI vs VRTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, VRTX has a market cap of 139B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while VRTX trades at $547.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas VRTX's P/E ratio is 28.78. In terms of profitability, MRVI's ROE is -0.35%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, MRVI is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
MRVI vs REGN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, REGN has a market cap of 85.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while REGN trades at $828.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas REGN's P/E ratio is 18.16. In terms of profitability, MRVI's ROE is -0.35%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MRVI is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
MRVI vs VRNA Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MRVI's ROE is -0.35%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, MRVI is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
MRVI vs ARGX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ARGX has a market cap of 62.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ARGX trades at $1,011.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ARGX's P/E ratio is 91.26. In terms of profitability, MRVI's ROE is -0.35%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, MRVI is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
MRVI vs MRNA Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, MRNA has a market cap of 55.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while MRNA trades at $138.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas MRNA's P/E ratio is -17.04. In terms of profitability, MRVI's ROE is -0.35%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, MRVI is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
MRVI vs RVMDW Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, RVMDW has a market cap of 47.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while RVMDW trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas RVMDW's P/E ratio is -1.69. In terms of profitability, MRVI's ROE is -0.35%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, MRVI is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
MRVI vs RVMD Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, RVMD has a market cap of 45B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while RVMD trades at $211.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas RVMD's P/E ratio is -23.99. In terms of profitability, MRVI's ROE is -0.35%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, MRVI is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
MRVI vs SGEN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRVI's ROE is -0.35%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRVI is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
MRVI vs ONC Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ONC has a market cap of 39.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ONC trades at $371.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ONC's P/E ratio is 65.49. In terms of profitability, MRVI's ROE is -0.35%, compared to ONC's ROE of +0.14%. Regarding short-term risk, MRVI is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
MRVI vs ALNY Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ALNY has a market cap of 31.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ALNY trades at $236.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ALNY's P/E ratio is 42.52. In terms of profitability, MRVI's ROE is -0.35%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, MRVI is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
MRVI vs BNTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, BNTX has a market cap of 28.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while BNTX trades at $112.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas BNTX's P/E ratio is -14.63. In terms of profitability, MRVI's ROE is -0.35%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, MRVI is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
MRVI vs INSM Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, INSM has a market cap of 26.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while INSM trades at $123.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas INSM's P/E ratio is -30.17. In terms of profitability, MRVI's ROE is -0.35%, compared to INSM's ROE of -1.11%. Regarding short-term risk, MRVI is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
MRVI vs ROIV Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ROIV has a market cap of 26.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ROIV trades at $36.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ROIV's P/E ratio is -34.59. In terms of profitability, MRVI's ROE is -0.35%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, MRVI is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
MRVI vs INCY Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, INCY has a market cap of 25.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while INCY trades at $127.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas INCY's P/E ratio is 17.20. In terms of profitability, MRVI's ROE is -0.35%, compared to INCY's ROE of +0.30%. Regarding short-term risk, MRVI is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
MRVI vs UTHR Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, UTHR has a market cap of 21.8B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while UTHR trades at $513.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas UTHR's P/E ratio is 18.36. In terms of profitability, MRVI's ROE is -0.35%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, MRVI is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
MRVI vs GMAB Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, GMAB has a market cap of 20.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while GMAB trades at $33.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas GMAB's P/E ratio is 24.88. In terms of profitability, MRVI's ROE is -0.35%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, MRVI is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
MRVI vs BGNE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRVI's ROE is -0.35%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, MRVI is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
MRVI vs DNA-WT Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRVI's ROE is -0.35%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, MRVI is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
MRVI vs JAZZ Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while JAZZ trades at $254.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas JAZZ's P/E ratio is 9.49. In terms of profitability, MRVI's ROE is -0.35%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, MRVI is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
MRVI vs BBIO Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, BBIO has a market cap of 15.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while BBIO trades at $81.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas BBIO's P/E ratio is -21.68. In terms of profitability, MRVI's ROE is -0.35%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, MRVI is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
MRVI vs ASND Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ASND has a market cap of 15.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ASND trades at $251.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ASND's P/E ratio is -104.11. In terms of profitability, MRVI's ROE is -0.35%, compared to ASND's ROE of +1.90%. Regarding short-term risk, MRVI is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
MRVI vs NBIX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while NBIX trades at $153.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas NBIX's P/E ratio is 22.12. In terms of profitability, MRVI's ROE is -0.35%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, MRVI is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
MRVI vs EXEL Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, EXEL has a market cap of 13.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while EXEL trades at $54.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas EXEL's P/E ratio is 15.59. In terms of profitability, MRVI's ROE is -0.35%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, MRVI is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check EXEL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
MRVI vs HALO Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, HALO has a market cap of 12.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while HALO trades at $108.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas HALO's P/E ratio is 20.27. In terms of profitability, MRVI's ROE is -0.35%, compared to HALO's ROE of +1.81%. Regarding short-term risk, MRVI is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
MRVI vs KRTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRVI's ROE is -0.35%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRVI is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
MRVI vs BMRN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, BMRN has a market cap of 12.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while BMRN trades at $65.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas BMRN's P/E ratio is 31.28. In terms of profitability, MRVI's ROE is -0.35%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, MRVI is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check BMRN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
MRVI vs ARWR Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ARWR trades at $86.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ARWR's P/E ratio is -38.55. In terms of profitability, MRVI's ROE is -0.35%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, MRVI is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
MRVI vs MDGL Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while MDGL trades at $511.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas MDGL's P/E ratio is -40.00. In terms of profitability, MRVI's ROE is -0.35%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, MRVI is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
MRVI vs TECH Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while TECH trades at $72.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas TECH's P/E ratio is 37.31. In terms of profitability, MRVI's ROE is -0.35%, compared to TECH's ROE of +0.09%. Regarding short-term risk, MRVI is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
MRVI vs RNAM Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MRVI's ROE is -0.35%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MRVI is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
MRVI vs AXSM Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while AXSM trades at $205.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas AXSM's P/E ratio is -53.63. In terms of profitability, MRVI's ROE is -0.35%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, MRVI is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check AXSM's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
MRVI vs IONS Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, IONS has a market cap of 10.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while IONS trades at $62.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas IONS's P/E ratio is -36.07. In terms of profitability, MRVI's ROE is -0.35%, compared to IONS's ROE of -1.11%. Regarding short-term risk, MRVI is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
MRVI vs PRAX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while PRAX trades at $368.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas PRAX's P/E ratio is -28.46. In terms of profitability, MRVI's ROE is -0.35%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, MRVI is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check PRAX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
MRVI vs SMMT Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while SMMT trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas SMMT's P/E ratio is -11.37. In terms of profitability, MRVI's ROE is -0.35%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, MRVI is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
MRVI vs KRYS Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while KRYS trades at $341.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas KRYS's P/E ratio is 42.82. In terms of profitability, MRVI's ROE is -0.35%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MRVI is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
MRVI vs KYMR Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while KYMR trades at $121.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas KYMR's P/E ratio is -37.83. In terms of profitability, MRVI's ROE is -0.35%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, MRVI is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
MRVI vs PTGX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while PTGX trades at $154.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas PTGX's P/E ratio is 150.21. In terms of profitability, MRVI's ROE is -0.35%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, MRVI is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
MRVI vs CYTK Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CYTK trades at $77.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CYTK's P/E ratio is -10.68. In terms of profitability, MRVI's ROE is -0.35%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, MRVI is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
MRVI vs RXDX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRVI's ROE is -0.35%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRVI is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
MRVI vs SYRE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, SYRE has a market cap of 9.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while SYRE trades at $106.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas SYRE's P/E ratio is -54.69. In terms of profitability, MRVI's ROE is -0.35%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, MRVI is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check SYRE's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
MRVI vs NUVL Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas NUVL's P/E ratio is -21.79. In terms of profitability, MRVI's ROE is -0.35%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MRVI is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
MRVI vs CRNX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CRNX trades at $84.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CRNX's P/E ratio is -16.82. In terms of profitability, MRVI's ROE is -0.35%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MRVI is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CRNX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
MRVI vs IMVT Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, IMVT has a market cap of 8.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while IMVT trades at $43.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas IMVT's P/E ratio is -15.36. In terms of profitability, MRVI's ROE is -0.35%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, MRVI is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
MRVI vs PCVX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while PCVX trades at $61.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas PCVX's P/E ratio is -8.11. In terms of profitability, MRVI's ROE is -0.35%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, MRVI is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
MRVI vs IMGN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRVI's ROE is -0.35%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MRVI is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
MRVI vs TGTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while TGTX trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas TGTX's P/E ratio is 20.29. In terms of profitability, MRVI's ROE is -0.35%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, MRVI is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check TGTX's competition here
Abivax S.A. (NASDAQ: ABVX)
MRVI vs ABVX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ABVX trades at $116.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ABVX's P/E ratio is -60.88. In terms of profitability, MRVI's ROE is -0.35%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MRVI is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
MRVI vs BPMC Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MRVI's ROE is -0.35%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, MRVI is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
MRVI vs APGE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while APGE trades at $134.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas APGE's P/E ratio is -31.13. In terms of profitability, MRVI's ROE is -0.35%, compared to APGE's ROE of -0.30%. Regarding short-term risk, MRVI is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
MRVI vs ALKS Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ALKS trades at $48.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ALKS's P/E ratio is 51.44. In terms of profitability, MRVI's ROE is -0.35%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, MRVI is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
MRVI vs CERE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRVI's ROE is -0.35%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MRVI is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
MRVI vs IBRX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while IBRX trades at $7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas IBRX's P/E ratio is -7.81. In terms of profitability, MRVI's ROE is -0.35%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, MRVI is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
MRVI vs RYTM Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, RYTM has a market cap of 7.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while RYTM trades at $111.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas RYTM's P/E ratio is -35.83. In terms of profitability, MRVI's ROE is -0.35%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, MRVI is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
MRVI vs MTSR Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MRVI's ROE is -0.35%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, MRVI is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
MRVI vs CAI Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CAI trades at $26.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CAI's P/E ratio is 73.42. In terms of profitability, MRVI's ROE is -0.35%, compared to CAI's ROE of +0.19%. Regarding short-term risk, MRVI is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CAI's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
MRVI vs SRRK Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, SRRK has a market cap of 7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while SRRK trades at $58.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas SRRK's P/E ratio is -16.87. In terms of profitability, MRVI's ROE is -0.35%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, MRVI is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
MRVI vs CGON Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CGON trades at $78.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CGON's P/E ratio is -29.08. In terms of profitability, MRVI's ROE is -0.35%, compared to CGON's ROE of -0.25%. Regarding short-term risk, MRVI is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
MRVI vs MRUS Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MRVI's ROE is -0.35%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, MRVI is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
MRVI vs ACLX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MRVI's ROE is -0.35%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MRVI is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
MRVI vs RETA Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRVI's ROE is -0.35%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRVI is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
MRVI vs BLTE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while BLTE trades at $158.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas BLTE's P/E ratio is -84.96. In terms of profitability, MRVI's ROE is -0.35%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, MRVI is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
MRVI vs CNTA Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MRVI's ROE is -0.35%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MRVI is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CNTA's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
MRVI vs COGT Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, COGT has a market cap of 6.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while COGT trades at $36.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas COGT's P/E ratio is -17.17. In terms of profitability, MRVI's ROE is -0.35%, compared to COGT's ROE of -0.73%. Regarding short-term risk, MRVI is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check COGT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
MRVI vs ORKA Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ORKA has a market cap of 6.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ORKA trades at $102.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ORKA's P/E ratio is -52.79. In terms of profitability, MRVI's ROE is -0.35%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, MRVI is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
MRVI vs DNTH Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while DNTH trades at $110.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas DNTH's P/E ratio is -26.52. In terms of profitability, MRVI's ROE is -0.35%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, MRVI is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check DNTH's competition here
Erasca, Inc. (NASDAQ: ERAS)
MRVI vs ERAS Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ERAS trades at $17.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ERAS's P/E ratio is -18.92. In terms of profitability, MRVI's ROE is -0.35%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, MRVI is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
MRVI vs TVTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while TVTX trades at $65.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas TVTX's P/E ratio is -144.93. In terms of profitability, MRVI's ROE is -0.35%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, MRVI is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check TVTX's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
MRVI vs PTCT Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while PTCT trades at $71.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas PTCT's P/E ratio is -30.50. In terms of profitability, MRVI's ROE is -0.35%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, MRVI is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check PTCT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
MRVI vs MIRM Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while MIRM trades at $96.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas MIRM's P/E ratio is -6.65. In terms of profitability, MRVI's ROE is -0.35%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, MRVI is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
MRVI vs XENE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, XENE has a market cap of 5.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while XENE trades at $60.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas XENE's P/E ratio is -12.89. In terms of profitability, MRVI's ROE is -0.35%, compared to XENE's ROE of -0.44%. Regarding short-term risk, MRVI is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check XENE's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
MRVI vs DFTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, DFTX has a market cap of 5.7B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while DFTX trades at $43.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas DFTX's P/E ratio is N/A. In terms of profitability, MRVI's ROE is -0.35%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, MRVI is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check DFTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
MRVI vs LGND Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while LGND trades at $280.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas LGND's P/E ratio is 30.76. In terms of profitability, MRVI's ROE is -0.35%, compared to LGND's ROE of +0.20%. Regarding short-term risk, MRVI is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
MRVI vs CDTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MRVI's ROE is -0.35%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, MRVI is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
MRVI vs ABCM Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRVI's ROE is -0.35%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRVI is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
MRVI vs ISEE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRVI's ROE is -0.35%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRVI is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
MRVI vs CRSP Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CRSP trades at $57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CRSP's P/E ratio is -11.99. In terms of profitability, MRVI's ROE is -0.35%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, MRVI is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
MRVI vs APLS Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas APLS's P/E ratio is 38.35. In terms of profitability, MRVI's ROE is -0.35%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MRVI is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
MRVI vs ACAD Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ACAD trades at $29.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ACAD's P/E ratio is 13.36. In terms of profitability, MRVI's ROE is -0.35%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, MRVI is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
MRVI vs DYN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while DYN trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas DYN's P/E ratio is -8.07. In terms of profitability, MRVI's ROE is -0.35%, compared to DYN's ROE of -0.64%. Regarding short-term risk, MRVI is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check DYN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
MRVI vs EWTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while EWTX trades at $44.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas EWTX's P/E ratio is -24.17. In terms of profitability, MRVI's ROE is -0.35%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, MRVI is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
MRVI vs TERN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas TERN's P/E ratio is -51.41. In terms of profitability, MRVI's ROE is -0.35%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MRVI is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
MRVI vs FOLD Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MRVI's ROE is -0.35%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MRVI is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
MRVI vs AKRO Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MRVI's ROE is -0.35%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, MRVI is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check AKRO's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
MRVI vs PBLS Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, PBLS has a market cap of 4.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while PBLS trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas PBLS's P/E ratio is -43.67. In terms of profitability, MRVI's ROE is -0.35%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, MRVI is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check PBLS's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
MRVI vs ALPN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRVI's ROE is -0.35%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MRVI is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
MRVI vs CELC Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CELC trades at $90.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CELC's P/E ratio is -21.11. In terms of profitability, MRVI's ROE is -0.35%, compared to CELC's ROE of -3.51%. Regarding short-term risk, MRVI is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CELC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
MRVI vs ELVN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ELVN trades at $61.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ELVN's P/E ratio is -36.62. In terms of profitability, MRVI's ROE is -0.35%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, MRVI is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
MRVI vs RLAY Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while RLAY trades at $19.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas RLAY's P/E ratio is -12.59. In terms of profitability, MRVI's ROE is -0.35%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, MRVI is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check RLAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
MRVI vs AMLX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, AMLX has a market cap of 4.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while AMLX trades at $38.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas AMLX's P/E ratio is -25.43. In terms of profitability, MRVI's ROE is -0.35%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, MRVI is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check AMLX's competition here
Opthea Limited (NASDAQ: OPT)
MRVI vs OPT Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRVI's ROE is -0.35%, compared to OPT's ROE of +1.18%. Regarding short-term risk, MRVI is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
MRVI vs PRTC Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas PRTC's P/E ratio is -3.78. In terms of profitability, MRVI's ROE is -0.35%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, MRVI is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
MRVI vs MRTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MRVI's ROE is -0.35%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MRVI is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check MRTX's competition here
Veradermics, Incorporated (NYSE: MANE)
MRVI vs MANE Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while MANE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas MANE's P/E ratio is -31.31. In terms of profitability, MRVI's ROE is -0.35%, compared to MANE's ROE of -0.29%. Regarding short-term risk, MRVI is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check MANE's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
MRVI vs ADPT Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while ADPT trades at $25.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas ADPT's P/E ratio is -62.32. In terms of profitability, MRVI's ROE is -0.35%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, MRVI is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
MRVI vs TNGX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while TNGX trades at $24.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas TNGX's P/E ratio is -29.53. In terms of profitability, MRVI's ROE is -0.35%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, MRVI is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
MRVI vs TLX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while TLX trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas TLX's P/E ratio is 121.92. In terms of profitability, MRVI's ROE is -0.35%, compared to TLX's ROE of -0.02%. Regarding short-term risk, MRVI is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check TLX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
MRVI vs VKTX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while VKTX trades at $33.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas VKTX's P/E ratio is -7.13. In terms of profitability, MRVI's ROE is -0.35%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, MRVI is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check VKTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
MRVI vs LEGN Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, LEGN has a market cap of 3.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while LEGN trades at $20.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas LEGN's P/E ratio is -30.79. In terms of profitability, MRVI's ROE is -0.35%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, MRVI is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for MRVI.Check LEGN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
MRVI vs CPRX Comparison August 2026
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRVI stands at 2.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MRVI is priced at $8.43 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRVI currently has a P/E ratio of -44.37, whereas CPRX's P/E ratio is 12.30. In terms of profitability, MRVI's ROE is -0.35%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MRVI is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for MRVI.Check CPRX's competition here